Brief: Reviva Announces Regulatory Update Regarding The Development Of Brilaroxazine For The Treatment Of Schizophrenia
23/12/2025 13:19
Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O: REVIVA ANNOUNCES REGULATORY UPDATE REGARDING THE DEVELOPMENT OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA REVIVA PHARMACEUTICALS HOLDINGS INC - FDA RECOMMENDS SECOND PHASE 3 TRIAL FOR BRILAROXAZINE REVIVA PHARMACEUTICALS HOLDINGS INC - RECOVER-2 TRIAL PLANNED FOR H1 2026 Source text: ID:nGNX1SXkRN Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture